<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Leap Therapeutics, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Leap Therapeutics, Inc.

    Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Chris Mirabelli, Ph.D.
    • FOUNDED
      2011
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Phio Pharmaceuticals Corp.

    Phio Pharmaceuticals Corp.

    Phio Pharmaceuticals is focused on developing the next generation of immuno-oncolo...

    Phio Pharmaceuticals is focused on developing t...

    Filing Type:    PU
    China Biologic Products Holdings, Inc.

    China Biologic Products Holdings, Inc.

    China Biologic Products Holdings, Inc. (NASDAQ: CBPO), is a leading fully integrat...

    China Biologic Products Holdings, Inc. (NASDAQ:...

    Filing Type:    PU
    Powell Development Group Inc.

    Powell Development Group Inc.

    After a good friend contracted HIV, I thought how could this happen? I was both sh...

    After a good friend contracted HIV, I thought h...

    Amount Raised:    $163,741.76
    Fundraising Status:    EC
    Filing Type:    CF
    BioCryst Pharmaceuticals, Inc.

    BioCryst Pharmaceuticals, Inc.

    BioCryst Pharmaceuticals discovers novel, oral small-molecule medicines that treat...

    BioCryst Pharmaceuticals discovers novel, oral ...

    Filing Type:    PU
    ContraFect Corporation

    ContraFect Corporation

    ContraFect is a clinical-stage biotechnology company focused on discovering and de...

    ContraFect is a clinical-stage biotechnology co...

    Filing Type:    PU
    Infinity Pharmaceuticals, Inc.

    Infinity Pharmaceuticals, Inc.

    Infinity Pharmaceuticals, Inc. is an innovative biopharmaceutical company dedicate...

    Infinity Pharmaceuticals, Inc. is an innovative...

    Filing Type:    PU
    Anchiano Therapeutics Ltd.

    Anchiano Therapeutics Ltd.

    We are Anchiano Therapeutics, a pivotal-stage biopharmaceutical company focused on...

    We are Anchiano Therapeutics, a pivotal-stage b...

    Filing Type:    PU
    TrovaGene, Inc.

    TrovaGene, Inc.

    Trovagene is a clinical-stage, oncology therapeutics company, taking a precision m...

    Trovagene is a clinical-stage, oncology therape...

    Filing Type:    PU
    NextCure, Inc.

    NextCure, Inc.

    NextCure is a clinical-stage biopharmaceutical company committed to discovering an...

    NextCure is a clinical-stage biopharmaceutical ...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.